10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2015 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 29, 2016) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Revenues | $ 48,851 | 49,605 | 51,584 |
| Costs and expenses: | |||
| Cost of sales | 9,648 [1] | 9,577 | 9,586 |
| Selling, informational and administrative expenses | 14,809 | 14,097 | 14,355 |
| Research and development expenses | 7,690 | 8,393 | 6,678 |
| Amortization of intangible assets | 3,728 | 4,039 | 4,599 |
| Restructuring charges and certain acquisition-related costs | 1,152 | 250 | 1,182 |
| Other (income)/deductionsnet | 2,860 | 1,009 | (532) |
| Income from continuing operations before provision for taxes on income | 8,965 | 12,240 | 15,716 |
| Provision for taxes on income | 1,990 | 3,120 | 4,306 |
| Income from continuing operations | 6,975 | 9,119 | 11,410 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | 17 | (6) | 308 |
| Gain/(loss) on disposal of discontinued operationsnet of tax | (6) | 55 | 10,354 |
| Discontinued operationsnet of tax | 11 | 48 | 10,662 |
| Net income before allocation to noncontrolling interests | 6,986 | 9,168 | 22,072 |
| Less: Net income attributable to noncontrolling interests | 26 [2] | 32 | 69 |
| Net income attributable to Pfizer Inc. | 6,960 | 9,135 | 22,003 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.13 | 1.43 | 1.67 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.01 | 1.56 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.13 | 1.44 | 3.23 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.11 | 1.41 | 1.65 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.01 | 1.54 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.11 | 1.42 | 3.19 |
| Weighted-average sharesbasic | 6,176 | 6,346 | 6,813 |
| Weighted-average sharesdiluted | 6,257 | 6,424 | 6,895 |
| Cash dividends paid per common share (in dollars per share) | 1.12 | 1.04 | 0.96 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets. | |||
| [2] Amounts may not add due to rounding. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |